Alector, Inc. (ALEC)
$
2.76
-0.20 (-7.25%)
Key metrics
Financial statements
Free cash flow per share
-2.1521
Market cap
279.3 Million
Price to sales ratio
3.4432
Debt to equity
0.5547
Current ratio
3.7838
Income quality
1.8700
Average inventory
0
ROE
-1.1206
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s EBITDA is -$136,156,000.00 a key indicator of its operational profitability. Alongside this, Alector reported depreciation and amortization expenses of $8,841,000.00 reflecting the wear and tear of its assets. Its gross profit ratio stands at 0.91 illustrating the efficiency of the company’s production and sales operations. Furthermore, the diluted EPS is -$1.23 accounting for potential share dilution. The company's stock is identified with the symbol 'ALEC' in the market, making it accessible for investors interested in its innovative offerings. Alector’s product pipeline includes AL001, a humanized recombinant monoclonal antibody, currently in Phase III clinical trials for treating frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. Additionally, AL101 is undergoing Phase I clinical trials for neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company also has AL002, a product candidate in Phase II trials for Alzheimer's disease, and AL003, which is in Phase I trials. Moreover, AL044, aimed at MS4A4A, a risk gene for Alzheimer's, is in the development stage. Alector maintains a collaboration agreement with Adimab, LLC for antibody research and development, as well as a strategic collaboration with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies like AL001 and AL101. The stock is affordable at $3.06 making it suitable for budget-conscious investors. It also boasts a high average trading volume of 1,050,706.00 indicating strong liquidity. With a market capitalization of $279,345,120.00 Alector is classified as a small-cap player in the biopharmaceutical sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field.
Is Alector, Inc. (ALEC) a good investment?
Investing in Alector, Inc. (ALEC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Alector, Inc. (ALEC)'s stock forecast?
Analysts predict Alector, Inc. stock to fluctuate between $0.87 (low) and $6.37 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alector, Inc.'s market capitalization?
As of 2025-09-17, Alector, Inc.'s market cap is $279,345,120, based on 101,212,000 outstanding shares.
How does Alector, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alector, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alector, Inc. (ALEC) stock?
To buy Alector, Inc. (ALEC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALEC. Place an order (Market, Limit, etc.).
What is the best time to invest in Alector, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alector, Inc. perform in the last earnings report?
Revenue: $100,558,000 | EPS: -$1.23 | Growth: -21.15%.
Where can I find Alector, Inc.'s investor relations reports?
Visit https://www.alector.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alector, Inc.?
You can explore historical data from here
What is the all-time high and low for Alector, Inc. stock?
All-time high: $29.30 (2021-09-02) | All-time low: $0.87 (2025-04-09).
What are the key trends affecting Alector, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Alector, Inc. (NASDAQ:ALEC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of SMID-Cap Biotech here at the firm.
zacks.com
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
seekingalpha.com
Alector, Inc. (NASDAQ:ALEC ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Katie Hogan - Senior Director of Corporate Communication & Investor Relations Neil Berkley - Interim CFO & Chief Business Officer Saraswati Kenkare-Mitra - President and Head of Research & Development Conference Call Participants Alec Warren Stranahan - BofA Securities, Research Division Michael H. Riad - Morgan Stanley, Research Division Myles Robert Minter - William Blair & Company L.L.C.
zacks.com
Alector (ALEC) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.4 per share a year ago.
globenewswire.com
-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that its Chief Financial Officer (CFO), Marc Grasso, M.D., will conclude his tenure with the company, effective June 20, 2025, to pursue other opportunities. Neil Berkley, M.B.A., the company's Chief Business Officer, will assume the role of Interim CFO while continuing in his current position.
globenewswire.com
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role--
seekingalpha.com
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
zacks.com
Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.
See all news
